Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Bile Acid
96%
Fibroblast Growth Factor 21
81%
Fibroblast Growth Factor 1
75%
Mouse
72%
Mouse Model
70%
Fibroblast Growth Factor
64%
Fibroblast Growth Factor 19
55%
Steatosis
51%
Disease
43%
Non Insulin Dependent Diabetes Mellitus
40%
Membrane Protein
32%
Sargassum
32%
Drug Delivery System
32%
Neonatal Hyperbilirubinemia
32%
Ursodeoxycholic Acid
32%
Steroid Hormone
32%
Androgen
32%
Cannabinoid
32%
Endocrine Disruptor
32%
Alzheimer's Disease
32%
Amyloid Plaque
32%
Metabolic Disorder
26%
Side Effect
26%
Adverse Event
26%
Knockout Mouse
25%
Clinical Trial
25%
Cannabis
25%
Liver X Receptor
21%
Malignant Neoplasm
21%
Farnesoid X Receptor
19%
Bilirubin
19%
Phytol
19%
Insulin Resistance
18%
Prevalence
17%
Liver Disease
16%
N (2,3 Dihydroxypropoxy) 3,4 Difluoro 2 (2 Fluoro 4 Iodoanilino)benzamide
16%
Phytosterol
16%
Liver X Receptor Agonist
16%
Sex Hormone
12%
Dyslipidemia
12%
Endocannabinoid System
12%
Receptor Agonist
12%
Gunn Rat
12%
Peroxisome Proliferator Activated Receptor Alpha
12%
Liver Injury
12%
Ether Lipid
12%
Fatty Liver
12%
Preclinical Study
12%
Thiazolidinedione
12%
Biochemistry, Genetics and Molecular Biology
Mouse
70%
Fibroblast Growth Factor
64%
Bile Acid
51%
Homeostasis
48%
Mouse Model
38%
Lipid Metabolism
35%
Gene Expression
32%
Adipocyte
32%
Polypeptide N-Acetylgalactosaminyltransferase
32%
Sargassum
32%
Cannabinoid
32%
Metabolic Regulation
32%
Glycosylation
32%
GALNT2
32%
Glucose Transport
32%
Membrane Protein
32%
Bile Acid Metabolism
32%
Lipid Liver Level
32%
Liver X Receptor
32%
Amyloid
32%
Knockout Mouse
30%
Metabolic Pathway
29%
Cannabis Use
25%
Peroxisome
25%
Insulin Resistance
22%
Body Weight
22%
Prevalence
22%
Energy Metabolism
22%
FGF1
20%
Messenger RNA
19%
MAPK Signaling
16%
FGF21
16%
Signal Transduction
16%
Comorbidity
16%
Drug Mechanism
16%
FGF19
16%
Life Expectancy
16%
Lipid
15%
Receptor Agonists
13%
Phytosterol
13%
Metabolite
12%
Endocannabinoid System
12%
Peroxisome Proliferator-Activated Receptor Alpha
12%
Isoform
12%
Alpha Oxidation
12%
Ether Lipid
12%
Glucose Transporter
9%
3T3-L1
9%
Liver X Receptor Beta
9%
Bile Composition
8%
Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
46%
Pegbelfermin
38%
PEGylated
32%
Mouse Model
32%
Steatosis
32%
Bile Acids
32%
Fibroblast Growth Factor 1 (FGF1)
32%
Amyloid Plaque Load
32%
Sargassum Fusiforme
32%
Neonatal Hyperbilirubinemia
32%
Ursodeoxycholic Acid
32%
Fibroblast Growth Factor 21 (FGF21)
32%
Effective Treatment
32%
Steatohepatitis
32%
Nonalcoholic Steatohepatitis
32%
PD0325901
32%
Farnesoid X Receptor
19%
Bilirubin
19%
Saringosterol
16%
Recombinant
16%
Gunn Rat
12%
Pristanic Acid
12%
Adverse Effects
12%
Thiazolidinediones
12%
Peroxisome Proliferator-activated Receptor
12%
Allreduce
10%
Liver Disease
9%
Cirrhosis
9%
Insulin Resistance
8%
Hepatic Steatosis
8%
Lipid Catabolism
8%
Triclocarban
8%
Cue-induced Reinstatement
7%
Drug-induced Reinstatement
7%
GW4064
6%
Treatment Options
6%
Protein Level
6%
Neurological Injury
6%
Preventive Treatment
6%
Postnatal Day
6%
LY2405319
6%
Humanized Mice
6%
NGM282
6%
Conventional Phototherapy
6%
Obeticholic Acid
6%
Exchange Transfusion
6%
Indirect Activation
6%
Ethyl
6%
Kernicterus
6%
Neonatal Jaundice
6%
